NCT01888497View on ClinicalTrials.gov

Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers

PHASE3CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

July 29, 2013

Primary Completion Date

December 14, 2013

Study Completion Date

December 14, 2013

Conditions
Healthy
Interventions
DRUG

Gabapentin

250 mg, oral, prior to bedtime on the night before performance testing

DRUG

Diphenhydramine citrate

76 mg, oral, prior to bedtime on the night before performance testing

DRUG

Triazolam

0.5 mg, oral, prior to bedtime on the night before performance testing

DRUG

Placebo

Oral, prior to bedtime on the night before performance testing

Trial Locations (4)

30342

NeuroTrials Research Sleep Lab, Atlanta

NeuroTrials Research, Inc., Atlanta

33143

Baptist Sleep Centers, LLP, South Miami

Miami Research Associates, South Miami

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT01888497 - Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers | Biotech Hunter | Biotech Hunter